FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeremy Hobart

Research Profile

Procedures

Disorders

Concepts & Ideas

Activities & Behaviors

Occupations

Evidence-Based Medicine

Co-author Network

Publications

TOP 3
Jeremy C Hobart; Stefan J Cano; Thomas T Warner; Alan J Thompson
What sample sizes for reliability and validity studies in neurology?
John Peter Zajicek; David Barnes; Jeremy C Hobart; Paul G Mattison; Anita Slade
Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
Stina Bladh; Gun-Marie Hariz; Jeremy C Hobart; Maria H Nilsson; Albert Westergren; Peter Hagell
Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeremy Hobart (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jeremy C Hobart; Stefan J Cano; Thomas T Warner; Alan J Thompson
What sample sizes for reliability and validity studies in neurology?
Journal of neurology 2012;259(12):2681-94.
2012: John Peter Zajicek; David Barnes; Jeremy C Hobart; Paul G Mattison; Anita Slade
Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
Journal of neurology, neurosurgery, and psychiatry 2012;83(11):1125-32.
2012: Stina Bladh; Gun-Marie Hariz; Jeremy C Hobart; Maria H Nilsson; Albert Westergren; Peter Hagell
Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease.
Journal of neurology 2012;259(4):729-38.
2011: S J Cano; L E Barrett; John P Zajicek; Jeremy C Hobart
Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(2):214-22.
2011: Afsane Riazi; Alan J Thompson; Jeremy Chataway; Bernadette Porter; Jeremy C Hobart
A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS).
Health and quality of life outcomes 2011;9():80.
2011: Stefan J Cano; Jeremy C Hobart
The problem with health measurement.
Patient preference and adherence 2011;5():279-90.
2010: Stefan J Cano; Holly B Posner; Margaret L Moline; Stephen W Hurt; Jina Swartz; Tim Hsu; Jeremy C Hobart
The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.
Journal of neurology, neurosurgery, and psychiatry 2010;81(12):1363-8.
2010: Jeremy C Hobart; Stefan J Cano; Alan J Thompson
Effect sizes can be misleading: is it time to change the way we measure change?
Journal of neurology, neurosurgery, and psychiatry 2010;81(9):1044-8.
2010: John P Zajicek; Wendy M Ingram; Jane Vickery; Siobhan Creanor; Dave E Wright; Jeremy C Hobart
Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.
BMC neurology 2010;10():88.
2009: Stefan J Cano; Afsane Riazi; Anthony H V Schapira; J Mark Cooper; Jeremy C Hobart
Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies.
Movement disorders : official journal of the Movement Disorder Society 2009;24(7):984-92.
2009: Jeremy C Hobart; Stefan J Cano
Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods.
Health technology assessment (Winchester, England) 2009;13(12):iii, ix-x, 1-177.
2009: F A H van der Linden; J Jolijn Kragt; Jeremy C Hobart; Martin Klein; Alan J Thompson; Henk M van der Ploeg; Chris H Polman; Bernard M J Uitdehaag
The size of the treatment effect: do patients and proxies agree?
BMC neurology 2009;9():12.
2008: Stefan J Cano; Jeremy C Hobart
Watch out, watch out, the FDA are about.
Developmental medicine and child neurology 2008;50(6):408-9.
2008: Peter Hagell; Anna Lena Törnqvist; Jeremy C Hobart
Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data.
Journal of neurology 2008;255(2):246-54.
2008: Stefan J Cano; Thomas T Warner; Alan J Thompson; Kailash P Bhatia; Ray Fitzpatrick; Jeremy C Hobart
The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?
Health and quality of life outcomes 2008;6():58.
2007: Jeremy C Hobart; Stefan J Cano; John P Zajicek; Alan J Thompson
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations.
Lancet neurology 2007;6(12):1094-105.
2007: Anette Schrag; Caroline Selai; Chris Mathias; Philip Low; Jeremy C Hobart; Niall Brady; Niall Quinn
Measuring health-related quality of life in MSA: the MSA-QoL.
Movement disorders : official journal of the Movement Disorder Society 2007;22(16):2332-8.
2007: John Campbell; Rachel Winder; Suzanne H Richards; Jeremy C Hobart
Exploring the relationships between provision of welfare benefits advice and the health of elderly people: a longitudinal observational study and discussion of methodological issues.
Health & social care in the community 2007;15(5):454-63.
2007: Regina Katzenschlager; Anette Schrag; Andrew Evans; Alice J Manson; Camille B Carroll; D Ottaviani; Andrew J Lees; Jeremy C Hobart
Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure.
Neurology 2007;69(6):555-63.
2007: Jeremy C Hobart
Measuring outcomes in clinical trials of stroke: time for state-of-the-art clinical trials to reject state-of-the-ark rating scales.
Journal of neurology 2007;254(8):1119.
2007: Stefan J Cano; Alan J Thompson; Kailash Bhatia; Ray Fitzpatrick; Thomas T Warner; Jeremy C Hobart
Evidence-based guidelines for using the Short Form 36 in cervical dystonia.
Movement disorders : official journal of the Movement Disorder Society 2007;22(1):122-6.
2006: Stefan J Cano; Jeremy C Hobart; M Edwards; Ray Fitzpatrick; Kailash Bhatia; Alan J Thompson; Thomas T Warner
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia.
Neurology 2006;67(12):2230-2.
2006: Stefan J Cano; Rory O'Connor; Alan J Thompson; Jeremy C Hobart
Exploring disability rating scale responsiveness II: do more response options help?
Neurology 2006;67(11):2056-9.
2006: A Holland; Rory O'Connor; Alan J Thompson; E Diane Playford; Jeremy C Hobart
Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions?
Journal of neurology 2006;253(12):1594-602.
2006: Rachel Baron; Abdurrahim Elashaal; Tim Germon; Jeremy C Hobart
Measuring outcomes in cervical spine surgery: think twice before using the SF-36.
Spine 2006;31(22):2575-84.
2006: F A H van der Linden; J Jolijn Kragt; Jeremy C Hobart; Martin Klein; Alan J Thompson; Henk M van der Ploeg; Chris H Polman; Bernard Uitdehaag
Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life.
Journal of neurology, neurosurgery, and psychiatry 2006;77(10):1157-62.
2006: Afsane Riazi; Stefan J Cano; J Mark Cooper; Jane L Bradley; Anthony H V Schapira; Jeremy C Hobart
Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes?
Movement disorders : official journal of the Movement Disorder Society 2006;21(9):1396-403.
2006: Anette Schrag; Caroline Selai; Niall Quinn; Andrew J Lees; Irene Litvan; Anthony E Lang; Y Poon; James Bower; David J Burn; Jeremy C Hobart
Measuring quality of life in PSP: the PSP-QoL.
Neurology 2006;67(1):39-44.
2006: Jeremy Chataway; Bernadette Porter; Afsane Riazi; Dominic Heaney; Hilary Watt; Jeremy C Hobart; Alan Thompson
Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial.
Lancet neurology 2006;5(7):565-71.
2006: Jeremy C Hobart; Afsane Riazi; Alan J Thompson; I M Styles; W Ingram; P J Vickery; M Warner; P J Fox; John P Zajicek
Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).
Brain : a journal of neurology 2006;129(Pt 1):224-34.
2005: L Nicholl; Jeremy C Hobart; A F L Cramp; Andrea S Lowe-Strong
Measuring quality of life in multiple sclerosis: not as simple as it sounds.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(6):708-12.
2005: Stefan J Cano; Jeremy C Hobart; Paul E Hart; L V Prasad Korlipara; Anthony H V Schapira; J Mark Cooper
International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?
Movement disorders : official journal of the Movement Disorder Society 2005;20(12):1585-91.
2005: Jeremy C Hobart; Afsane Riazi; DL Lamping; Ray Fitzpatrick; Alan J Thompson
How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales.
Journal of neurology, neurosurgery, and psychiatry 2005;76(11):1539-43.
2005: Anette Schrag; Caroline Selai; Niall Quinn; Jeremy C Hobart
Measuring health-related quality of life in patients with progressive supranuclear palsy.
Neurocase 2005;11(4):246-9.
2005: Jennifer A Freeman; Jeremy C Hobart; E Diane Playford; B Undy; Alan J Thompson
Evaluating neurorehabilitation: lessons from routine data collection.
Journal of neurology, neurosurgery, and psychiatry 2005;76(5):723-8.
2004: Stefan J Cano; Thomas T Warner; J M Linacre; KP Bhatia; Alan J Thompson; Ray Fitzpatrick; Jeremy C Hobart
Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58).
Neurology 2004;63(9):1629-33.
2004: Camille B Carroll; Peter G Bain; LJ Teare; X Liu; Carole Joint; C Wroath; Simon G Parkin; Patrick Fox; Dave Wright; Jeremy C Hobart; John Zajicek
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.
Neurology 2004;63(7):1245-50.
2004: Stefan J Cano; Jeremy C Hobart; Ray Fitzpatrick; Kailash Bhatia; Alan J Thompson; Thomas T Warner
Patient-based outcomes of cervical dystonia: a review of rating scales.
Movement disorders : official journal of the Movement Disorder Society 2004;19(9):1054-9.
2004: L Nicholl; Jeremy C Hobart; L Dunwoody; F Cramp; Andrea S Lowe-Strong
Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(4):447-50.
2004: Rory O'Connor; Stefan J Cano; Alan J Thompson; Jeremy C Hobart
Exploring rating scale responsiveness: does the total score reflect the sum of its parts?
Neurology 2004;62(10):1842-4.
2004: C Carroll; Jeremy C Hobart; C Fox; LJ Teare; J Gibson
Stroke in Devon: knowledge was good, but action was poor.
Journal of neurology, neurosurgery, and psychiatry 2004;75(4):567-71.
2004: Jeremy C Hobart; Afsane Riazi; DL Lamping; Ray Fitzpatrick; Alan J Thompson
Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
Health technology assessment (Winchester, England) 2004;8(9):iii, 1-48.
2004: Afsane Riazi; Alan J Thompson; Jeremy C Hobart
Self-efficacy predicts self-reported health status in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(1):61-6.
2004: Jeremy C Hobart; N Kalkers; F Barkhof; Bernard Uitdehaag; C Polman; A Thompson
Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(1):41-6.
2003: Jeremy C Hobart
Rating scales for neurologists.
Journal of neurology, neurosurgery, and psychiatry 2003;74 Suppl 4():iv22-iv26.
2003: Afsane Riazi; Jeremy C Hobart; Ray Fitzpatrick; Jennifer A Freeman; Alan J Thompson
Socio-demographic variables are limited predictors of health status in multiple sclerosis.
Journal of neurology 2003;250(9):1088-93.
2003: Helen Mundy; S J Jones; Jeremy C Hobart; M G Hanna; Philip J Lee
A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.
Neurology 2003;61(4):528-30.
2003: Afsane Riazi; Jeremy C Hobart; DL Lamping; Ray Fitzpatrick; Alan J Thompson
Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(4):411-9.
2003: Afsane Riazi; Jeremy C Hobart; DL Lamping; Ray Fitzpatrick; Jennifer A Freeman; C Jenkinson; V Peto; Alan J Thompson
Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles.
Journal of neurology, neurosurgery, and psychiatry 2003;74(6):710-4.
2003: Jeremy C Hobart; Afsane Riazi; DL Lamping; Ray Fitzpatrick; Alan J Thompson
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).
Neurology 2003;60(1):31-6.
2002: Jeremy C Hobart
Measuring disease impact in disabling neurological conditions: are patients' perspectives and scientific rigor compatible?
Current opinion in neurology 2002;15(6):721-4.
2002: Afsane Riazi; Jeremy C Hobart; DL Lamping; Ray Fitzpatrick; Alan J Thompson
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.
Journal of neurology, neurosurgery, and psychiatry 2002;73(6):701-4.
2002: S G M Edwards; E Diane Playford; Jeremy C Hobart; Alan J Thompson
Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation.
BMJ (Clinical research ed.) 2002;324(7352):1493.
2002: Jeremy C Hobart; Linda S Williams; Kimberly Moran; Alan J Thompson
Quality of life measurement after stroke: uses and abuses of the SF-36.
Stroke; a journal of cerebral circulation 2002;33(5):1348-56.
2002: Crispin Jenkinson; Jeremy C Hobart; Tarani Chandola; Ray Fitzpatrick; Viv Peto; Michael Swash
Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions.
Journal of neurology 2002;249(2):178-83.
2001: Jeremy C Hobart; J Freeman; DL Lamping; Ray Fitzpatrick; Alan Thompson
The SF-36 in multiple sclerosis: why basic assumptions must be tested.
Journal of neurology, neurosurgery, and psychiatry 2001;71(3):363-70.
2001: Jeremy C Hobart; DL Lamping; Jennifer A Freeman; DW Langdon; D L McLellan; Richard J Greenwood; Alan J Thompson
Evidence-based measurement: which disability scale for neurologic rehabilitation?
Neurology 2001;57(4):639-44.
2001: Jeremy C Hobart; Alan J Thompson
The five item Barthel index.
Journal of neurology, neurosurgery, and psychiatry 2001;71(2):225-30.
2001: Jennifer A Freeman; Jeremy C Hobart; Alan J Thompson
Does adding MS-specific items to a generic measure (the SF-36) improve measurement?
Neurology 2001;57(1):68-74.
2001: Jeremy C Hobart; DL Lamping; Ray Fitzpatrick; Afsane Riazi; Alan Thompson
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
Brain : a journal of neurology 2001;124(Pt 5):962-73.
2001: Alice J Manson; Regina Katzenschlager; Jeremy C Hobart; Andrew J Lees
High dose naltrexone for dyskinesias induced by levodopa.
Journal of neurology, neurosurgery, and psychiatry 2001;70(4):554-6.
2000: Jeremy C Hobart; J Freeman; Alan Thompson
Kurtzke scales revisited: the application of psychometric methods to clinical intuition.
Brain : a journal of neurology 2000;123 ( Pt 5)():1027-40.
2000: Jennifer A Freeman; Jeremy C Hobart; DW Langdon; Alan J Thompson
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2000;68(2):150-6.
1999: J J van der Putten; Jeremy C Hobart; Jennifer A Freeman; Alan J Thompson
Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the Functional Independence Measure.
Journal of neurology, neurosurgery, and psychiatry 1999;66(4):480-4.
1999: Jennifer A Freeman; DW Langdon; Jeremy C Hobart; Alan J Thompson
Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?
Neurology 1999;52(1):50-6.
1998: Alan J Thompson; Jeremy C Hobart
Multiple sclerosis: assessment of disability and disability scales.
Journal of neurology 1998;245(4):189-96.
1997: Jennifer A Freeman; DW Langdon; Jeremy C Hobart; Alan J Thompson
The impact of inpatient rehabilitation on progressive multiple sclerosis.
Annals of neurology 1997;42(2):236-44.
1997: Jeremy C Hobart; A Thompson
A comparison of two neurologic scoring instruments for multiple sclerosis.
Journal of neurology 1997;244(1):60-1.
1996: Jeremy C Hobart; Jennifer A Freeman; D L Lamping
Physician and patient-oriented outcomes in progressive neurological disease: which to measure?
Current opinion in neurology 1996;9(6):441-4.
1996: J A Freeman; Jeremy C Hobart; A J Thompson
Outcomes-based research in neurorehabilitation: the need for multidisciplinary team involvement.
Disability and rehabilitation 1996;18(2):106-10.
1996: Jeremy C Hobart; D L Lamping; Alan J Thompson
Evaluating neurological outcome measures: the bare essentials.
Journal of neurology, neurosurgery, and psychiatry 1996;60(2):127-30.